lenvatinib: Clinical Trials

535 trials of lenvatinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

143 completed, 125 recruiting, 94 unknown, 64 active not recruiting. 349 Phase 2, 103 Phase 1, 65 Phase 3, 29 Not applicable, 11 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2349Recruiting 91, Completed 75, Unknown 53, Active not recruiting 48, Not yet recruiting 48, Terminated 16, Withdrawn 15, Suspended 3
Phase 1103Completed 46, Recruiting 18, Unknown 14, Active not recruiting 11, Not yet recruiting 6, Terminated 5, Withdrawn 3
Phase 365Completed 21, Recruiting 12, Unknown 12, Active not recruiting 7, Not yet recruiting 6, Terminated 3, Withdrawn 3, Suspended 1
Not applicable29Unknown 14, Recruiting 5, Completed 4, Not yet recruiting 4, Active not recruiting 1, Withdrawn 1
Phase 411Not yet recruiting 3, Recruiting 3, Unknown 3, Completed 2
Early Phase 19Unknown 4, Recruiting 2, Active not recruiting 1, Completed 1, Enrolling by invitation 1

Follow lenvatinib: new trials by email Literature Review of lenvatinib trials Research Report on lenvatinib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
EG-007, Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection, Lenvatinib Capsules - Advanced Endometrial Cancer
Phase 3Not yet recruitingEvergreen Therapeutics, Inc.4502026-12-012025-12-08
PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC
Lenvatinib, Partial transarterial chemoembolization (TACE) - Hepatocellular Carcinoma
Phase 2Not yet recruitingChang Gung Memorial Hospital402026-11-302026-11-03
Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors
QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer
Phase 1 / Phase 2Not yet recruitingQilu Pharmaceutical Co., Ltd.5582026-11-152026-11-12
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Toripalimab, Lenvatinib, Stereotactic Body Radiotherapy - Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
Phase 2Not yet recruitingSun Yat-sen University362026-11-102026-11-06
Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma
Pucotenlimab, Lenvatinib, Stereotactic Body Radiotherapy - Localized Clear Cell Renal Cell Carcinoma
Phase 2Not yet recruitingSun Yat-sen University242026-11-102026-11-06
Lenvatinib in Patients With Advanced Parathyroid Carcinoma
Lenvatinib - Parathyroid Carcinoma
Phase 2Not yet recruitingYonsei University182026-11-012026-09-28
Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer
Lenvatinib, Tislelizumab, Gefitinib - Hepatocellular Carcinoma (HCC)
Phase 2Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical University1202026-11-012026-09-21
Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.
QL1706 (Iparomlimab/Tuvonralimab), Lenvatinib, Cryoablation - Biliary Tract Cancer (BTC)
Phase 2RecruitingFudan University1802026-10-262026-11-17
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma
BGB-B2033, Lenvatinib, Sorafenib - Hepatocellular Carcinoma, Liver Cancer
Phase 3RecruitingBeOne Medicines4922026-10-232026-11-10
Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) Plus Low-Dose Lenvatinib, Iparomlimab and Tuvonralimab, and SBRT in Hepatocellular Carcinoma With Macrovascular Tumor Thrombus
BMS-TACE, Lenvatinib, Iparomlimab and Tuvonralimab - Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
Phase 2RecruitingSun Yat-sen University422026-10-152026-11-20
Safety and Efficacy of Gemcitabine, Toripalimab and Dose- Modified Lenvatinib in Elderly Patients With Advanced Biliary Tract Cancer Intolerant to Conventional Chemotherapy
gemcitabine, toripalimab, and lenvatinib capsules - Advanced Biliary Tract Cancer
Phase 2Not yet recruitingShanghai Zhongshan Hospital392026-10-122026-10-27
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Iparomlimab and Tuvonralimab (QL1706), Lenvatinib, Radiotherapy - HCC - Hepatocellular Carcinoma
Phase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology352026-10-012026-09-15
Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial
Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine - Melanoma (Skin) Stage IV
Phase 2RecruitingSun Yat-sen University282026-10-012026-09-29
Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical Study
Gematinib, Lenvatinib - Non-Small Cell Lung Cancer
Phase 2Not yet recruitingPeking University Cancer Hospital & Institute232026-09-302026-10-26
Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer
Lenvatinib, Pembrolizumab - Anal Squamous Cell Carcinoma
Phase 2Not yet recruitingUniversity of Texas Southwestern Medical Center172026-09-302026-07-02
MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer
Becotatug Vedotin (MRG003), Lenvatinib, Anti-PD-1 Inhibitor (Continuation of Prior Treatment) - Thyroid Cancer, Tumor
Phase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University392026-09-202026-10-14
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Gemcitabine, Cisplatin, Tislelizumab - Intrahepatic Cholangiocarcinoma (Icc)
Phase 3Not yet recruitingZhejiang Cancer Hospital1402026-09-012026-10-26
Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib - HCC - Hepatocellular Carcinoma
Phase 2RecruitingTianjin Medical University Cancer Institute and Hospital202026-09-012026-09-03
A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma
Iparomlimab and Tuvonralimab in combination with Lenvatinib - Urologic Neoplasms
Phase 2Not yet recruitingThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School542026-08-152026-08-03
STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation
Lenvatinib, TMZ (Temozolomide), radiotherapy - Glioma, Glioblastoma (GBM)
Phase 2Not yet recruitingDongguan People's Hospital1382026-08-102026-08-10

Showing 20 of 535. Sign in to see all of them.

Conditions studied

Carcinoma, Hepatocellular (154)  ·  Carcinoma, Renal Cell (42)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (34)  ·  Neoplasms (30)  ·  Cholangiocarcinoma (28)  ·  Endometrial Neoplasms (19)  ·  Liver Neoplasms (19)  ·  Thyroid Neoplasms (18)  ·  Biliary Tract Neoplasms (16)  ·  Melanoma (16)  ·  Carcinoma, Non-Small-Cell Lung (14)  ·  Stomach Neoplasms (13)  ·  Neoplasm Metastasis (10)  ·  Recurrence (10)  ·  Ovarian Neoplasms (9)

Sponsors

Merck Sharp & Dohme LLC (45)  ·  Eisai Inc. (43)  ·  Sun Yat-sen University (43)  ·  Fudan University (26)  ·  Tianjin Medical University Cancer Institute and Hospital (18)  ·  Peking Union Medical College Hospital (15)  ·  Eisai Co., Ltd. (14)  ·  Tongji Hospital (11)  ·  M.D. Anderson Cancer Center (10)  ·  RenJi Hospital (8)  ·  Shanghai Zhongshan Hospital (8)  ·  Second Affiliated Hospital of Guangzhou Medical University (7)  ·  Chen Xiaoping (6)  ·  Memorial Sloan Kettering Cancer Center (6)  ·  Zhejiang Cancer Hospital (6)

Countries

China (273)  ·  United States (147)  ·  Spain (61)  ·  South Korea (59)  ·  Italy (57)  ·  Japan (57)  ·  France (56)  ·  Australia (49)  ·  United Kingdom (47)  ·  Canada (45)  ·  Germany (38)  ·  Taiwan (38)  ·  Russia (36)  ·  Poland (35)  ·  Israel (32)

Top investigators

Peng Wang, MD (8)  ·  Ming Shi, MD (7)  ·  Haitao Zhao, MD (3)  ·  Soo Chin Lee (3)  ·  Alan Ho, MD, PhD (2)  ·  Feng Duan, MD (2)  ·  Floor Backes, MD (2)  ·  Gaojun Teng, MD (2)  ·  Guoliang Shao, MD (2)  ·  Hao Feng, MD., Ph.D. (2)  ·  Jian Zhou (2)

Results publications

PMID 29433850, PMID 33300372, PMID 33198671, PMID 20375404, PMID 23860537, PMID 28818953, PMID 30207593, PMID 32265508, PMID 32716739, PMID 32832493, PMID 34087115, PMID 34416158, PMID 34562750, PMID 38039993, PMID 38159809, PMID 39941845, PMID 40812353, PMID 42167105, PMID 11282421, PMID 12778165, PMID 12806613, PMID 14667750, PMID 15043519, PMID 15319238, PMID 16557381, PMID 17410014, PMID 18596824, PMID 19095497, PMID 19097774, PMID 20930041, PMID 21372218, PMID 21502559, PMID 21847048, PMID 21847058, PMID 21874260, PMID 21953501, PMID 22339891, PMID 22525820, PMID 22537432, PMID 23043667, PMID 23485770, PMID 23676418, PMID 24146220, PMID 24681130, PMID 24769639, PMID 24852116, PMID 24974848, PMID 25027973, PMID 25047123, PMID 25275083

NIH funding

2023 (28), 2019 (12), 2018 (10), 2017 (7), 2015 (3), 2016 (3), P30CA015083 (3), 2025 (2), P30CA033572 (2), P30CA138292 (2), 2004 (1), 2009 (1), 2014 (1), U10CA180868 (1), U10CA180888 (1)